ABVC BIOPHARMA, INC. (ABVC): Nasdaq/NYSE listing notice — ABVC BioPharma regains Nasdaq minimum bid price compliance, delisting risk removed

ABVC BIOPHARMA, INC.

Received Nasdaq notification on Aug 8, 2023 confirming compliance with Rule 5550(a)(2).
Closing bid price was $1.00 or above for 10 consecutive days (July 25 – Aug 7, 2023).
Previously received deficiency letter on Aug 19, 2022; compliance deadline extended to Aug 14, 2023.
Matter now closed; no further action required by Nasdaq.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 8, 2023, the Company received a notification letter (the “ Notification Letter ”) from Nasdaq notifying the Company that the Staff has determined that for 10 consecutive business days, from July 25, 2023 to August 7, 2023, the closing bid price of the Company’s common stock has been at least $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Listing Rule 5550(a)(2) and has indicated that the matter is now closed. On August 10, 2023, the Company shall issue a press release announcing that the Company received the Notification L

View on SEC.gov

Browse all listing & compliance notices →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-065088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.